To continue receiving our emails, add us to your address book.

Washington, DC | 20036 US
1233 20th St., N.W., Suite 303
View this email
Got this as a forward?
Manage

Share this email:

Additional tools and resources at its website soon.
strategies to stem rising health system costs and will feature NASHP continues to work with states to develop a variety answer questions during this off-the-record forum for state leaders. Sudders will strengthening the state’s cost-growth benchmark and subjecting Value that aims to manage health care cost drivers, in part by through Massachusetts’ Act to Improve Health Care by Investing in Services Marylou Sudders (pictured). She will walk policymakers NASHP is sponsoring a state officials-only webinar featuring Secretary of Massachusetts Executive Office of Health and Human

State Transparency Laws Identify Costly Drugs, including Those with Unsupported Price Hikes
The same costly drugs identified by state transparency reports also appear in an independent research institute’s report on drugs whose rapidly rising prices are not supported by new clinical evidence. At the same time, the Institute for Clinical and Economic Review (ICER) has identified these costliest drugs. This blog highlights the value of state transparency laws in shining a light on drugs creating the greatest affordability challenges for states.

New Tool Helps States Leverage Prescription Drug Purchasing Power
An official explores leveraging their collective buying power to help states achieve greater value in specialty drug purchasing. This blog highlights a new tool developed by the National Academy for State Health Policy (NASHP) for Conducting Public Purchasing of Prescription Drugs to help states identify low-cost, high-quality drugs and identify opportunities for coordination. This blog highlights how the checklist has been adopted by states to gather critical data on purchasers’ opportunities for coordination with pharmacy benefit managers, determine how much is spent on drugs based on net cost and utilization, and better understand each purchaser’s prescription drug benefits.

NASHP News | November 5, 2019

NASHP is sponsoring a state officials-only webinar featuring Secretary of Massachusetts Executive Office of Health and Human Services Marylou Sudders (pictured). She will walk policymakers through Massachusetts’ Act to Improve Health Care by Investing in Services, and explain how the state achieved certain high-cost drugs to an accountability process. Sudders will strengthen the state’s cost-growth benchmark and subjecting Value that aims to manage health care cost drivers, in part by through Massachusetts’ Act to Improve Health Care by Investing in Services Marylou Sudders (pictured). She will walk policymakers NASHP is sponsoring a state officials-only webinar featuring Secretary of Massachusetts Executive Office of Health and Human

State Transparency Laws Identify Costly Drugs, including Those with Unsupported Price Hikes
The same costly drugs identified by state transparency reports also appear in an independent research institute’s report on drugs whose rapidly rising prices are not supported by new clinical evidence. At the same time, the Institute for Clinical and Economic Review (ICER) has identified these costliest drugs. This blog highlights the value of state transparency laws in shining a light on drugs creating the greatest affordability challenges for states.

New Tool Helps States Leverage Prescription Drug Purchasing Power
An official explores leveraging their collective buying power to help states achieve greater value in specialty drug purchasing. This blog highlights a new tool developed by the National Academy for State Health Policy (NASHP) for Conducting Public Purchasing of Prescription Drugs to help states identify low-cost, high-quality drugs and identify opportunities for coordination. This blog highlights how the checklist has been adopted by states to gather critical data on purchasers’ opportunities for coordination with pharmacy benefit managers, determine how much is spent on drugs based on net cost and utilization, and better understand each purchaser’s prescription drug benefits.

NASHP News | November 5, 2019

NASHP is sponsoring a state officials-only webinar featuring Secretary of Massachusetts Executive Office of Health and Human Services Marylou Sudders (pictured). She will walk policymakers through Massachusetts’ Act to Improve Health Care by Investing in Services, and explain how the state achieved certain high-cost drugs to an accountability process. Sudders will strengthen the state’s cost-growth benchmark and subjecting Value that aims to manage health care cost drivers, in part by through Massachusetts’ Act to Improve Health Care by Investing in Services Marylou Sudders (pictured). She will walk policymakers NASHP is sponsoring a state officials-only webinar featuring Secretary of Massachusetts Executive Office of Health and Human

State Transparency Laws Identify Costly Drugs, including Those with Unsupported Price Hikes
The same costly drugs identified by state transparency reports also appear in an independent research institute’s report on drugs whose rapidly rising prices are not supported by new clinical evidence. At the same time, the Institute for Clinical and Economic Review (ICER) has identified these costliest drugs. This blog highlights the value of state transparency laws in shining a light on drugs creating the greatest affordability challenges for states.

New Tool Helps States Leverage Prescription Drug Purchasing Power
An official explores leveraging their collective buying power to help states achieve greater value in specialty drug purchasing. This blog highlights a new tool developed by the National Academy for State Health Policy (NASHP) for Conducting Public Purchasing of Prescription Drugs to help states identify low-cost, high-quality drugs and identify opportunities for coordination. This blog highlights how the checklist has been adopted by states to gather critical data on purchasers’ opportunities for coordination with pharmacy benefit managers, determine how much is spent on drugs based on net cost and utilization, and better understand each purchaser’s prescription drug benefits.